CRISPR, CRSP and Therapeutics

Why CRISPR Therapeutics (CRSP) Soared on Friday?
We recently published a list of Shares of 10 Firms Soar on Friday. In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against other firms that soared on Friday.
CRISPR Therapeutics (NASDAQ:CRSP) Price Target Raised to $56.00
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target hoisted by Barclays from $55.00 to $56.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock.
CRISPR Therapeutics Stock Upgrade Following Analyst Reassessment
CRISPR Therapeutics (CRSP, Financials) stock rose 16.4% to $50.60 as of 10:10 a.m. GMT-5 on Friday, following an analyst upgrade. Citing pipeline advancements and possible catalysts, Evercore ISI analyst Liisa Bayko raised CRISpen Therapeutics from "In Line" to "Outperform.
Evercore ISI Group Upgrades CRISPR Therapeutics (CRSP)
Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (NasdaqGM:CRSP) from In-Line to Outperform. Analyst Price Forecast Suggests 90.46% Upside As of January 28,
Crispr Therapeutics upgraded to Outperform from In Line at Evercore ISI
Evercore ISI analyst Liisa Bayko upgraded Crispr Therapeutics (CRSP) to Outperform from In Line with a price target of $99, up from $60.
CRISPR Therapeutics stock rises following analyst upgrade
Evercore ISI analyst Liisa Bayko raised the price target for CRISPR Therapeutics from $60.00 to $99.00. Bayko's optimism is driven by upcoming catalysts that could mark a new chapter for the company.
CRISPR upped to outperform by Evercore on upcoming data
Evercore ISI has upgraded CRISPR Therapeutics (NASDAQ:CRSP) to outperform from in line, citing upcoming catalysts. The investment firm said it was now including the CTX320 and CTX310 in vivo programs in its price target,
Q4 Earnings Surprise Greenlights CRISPR Therapeutics Stock Climb
CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The ...
Citi cuts CRISPR Therapeutics price target to $82, keeps buy rating
Citi analysts adjusted their outlook on CRISPR Therapeutics (NASDAQ:CRSP) stock, reducing the price target to $82 from $89 while maintaining a Buy rating. The stock, which has shown significant ...
CRISPR Therapeutics upgraded to Outperform by Evercore ISI
CRISPR Therapeutics (CRSP) shares jump after Evercore ISI upgraded the stock to Outperform from In Line. Julie Hyman and Josh ...
CRISPR: From Discovery To Clinic—And Charting A Path Forward
No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...
Hosted on MSN2d
Crispr Therapeutics Faces Market Challenges Amidst BPCIA Biosimilar Risks
Crispr Therapeutics (CRSP) has disclosed a new risk, in the Innovation / R&D category. Crispr Therapeutics faces a significant business risk due ...
Stifel Nicolaus Sticks to Its Hold Rating for Crispr Therapeutics AG (CRSP)
Stifel Nicolaus analyst Benjamin Burnett maintained a Hold rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price ...
CRISPR upgraded to hold by TD Cowen on limited downside
TD Cowen has upgraded CRISPR Therapeutics (CRSP) to hold from sell, stating it now sees less downside to the stock. Read more ...